Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary sclerosing cholangitis.

Flavia D Mendes1, Keith D Lindor

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA.

Clinics in Liver Disease
|April 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Betaine in the treatment of steatotic liver disease-Historical fad or a timeless treasure worth reviving?

Hepatology (Baltimore, Md.)·2025
Same author

Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid.

JHEP reports : innovation in hepatology·2023
Same author

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.

Liver international : official journal of the International Association for the Study of the Liver·2023
Same author

Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.

Hepatology (Baltimore, Md.)·2023
Same author

Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.

The American journal of gastroenterology·2023
Same author

Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe.

European journal of gastroenterology & hepatology·2022
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Primary sclerosing cholangitis (PSC) is a liver disease linked to inflammatory bowel disease (IBD). While autoimmunity is implicated, its exact origins and effective treatments beyond liver transplantation remain unclear.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Immunology

Background:

  • Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease.
  • PSC exhibits a strong association with inflammatory bowel disease (IBD), particularly ulcerative colitis.
  • The pathogenesis of PSC is complex and not fully understood, though autoimmune factors are considered significant.

Purpose of the Study:

  • To review current understanding of PSC pathogenesis.
  • To discuss the role of autoimmunity in PSC development.
  • To evaluate therapeutic strategies and the role of liver transplantation.

Main Methods:

  • Literature review of recent research on PSC.
  • Analysis of immunological and genetic factors in PSC.

Related Experiment Videos

  • Evaluation of clinical trial data for PSC treatments.

    • Main Results:

    • Evidence supports an autoimmune component in genetically susceptible individuals.
    • Significant knowledge gaps persist regarding the precise etiology of PSC.
    • Current treatments aim to manage symptoms and slow progression, but none are curative.

    Conclusions:

    • PSC pathogenesis involves a complex interplay of genetic predisposition and immune dysregulation.
    • Liver transplantation remains the only definitive treatment offering survival benefit for advanced PSC.
    • Further research is crucial to identify novel therapeutic targets for PSC.